During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Darren Pan, Icahn School of Medicine at Mount Sinai, New York, US. We asked, Are chimeric antigen receptor (CAR) T-cell therapies effective in the treatment of extramedullary multiple myeloma?

Pan discusses the efficacy of CAR T-cell therapies in patients with multiple myeloma with varying degrees of extramedullary involvement; he considers how involvement influences initial responses, progression-free survival, and durability of response. Pan concludes by examining resistance factors to CAR T-cell therapies and highlighting areas that require further investigation in clinical trials.